Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Digestive and Liver Disease Année : 2020

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study

Pierre Michel
  • Fonction : Auteur

Domaines

Cancer

Dates et versions

hal-04548048 , version 1 (16-04-2024)

Identifiants

Citer

Sylvain Manfredi, Anthony Turpin, David Malka, Emilie Barbier, Pierre Laurent-Puig, et al.. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study. Digestive and Liver Disease, 2020, 52 (10), pp.1143-1147. ⟨10.1016/j.dld.2020.06.034⟩. ⟨hal-04548048⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More